Rituxan Off-Label Use Registry (IRB# 29270EP)
- Principal Investigator: Andrew S. Freiberg, MD
Rituxan (Anti-CD-20) is FDA approved as therapy for certain lymphomas. Its mechanism of action is to target normal and malignant B-lymphocytes, and has an acceptable safety profile. By targeting normal B-lymphocytes in theory the drug may be used to treat autoimmune diseases caused by antibodies produced by these lymphocytes.
The key objective is to determine the safety of Rituxan when used off-label, mostly for autoimmune diseases.
Any patient who in the course of standard clinical care has received or will receive Rituxan for an off-label use. All ages and both males and females are eligible.
Additional Study Details:
Data collection only. Data will include clinical course of underlying condition and side effects.
Penn State Milton S. Hershey Medical Center
Pediatric Clinical Research Office
- Hematology / Oncology